Apolipoprotein A-II (apoA-II) is the second major apolipoprotein following apolipoprotein A-I (apoA-I) in HDL. ApoA-II has multiple physiological functions and can form senile amyloid fibrils (AApoAII) in mice. Most circulating apoA-II is present in lipoprotein A-I/A-II. To study the influence of apoA-I on apoA-II and AApoAII amyloidosis, apoA-I deficient (C57BL/6J.Apoa1 -/-) mice were used. Apoa1 -/-mice showed the expected significant reduction in total cholesterol (TC), HDL cholesterol (HDL-C) and triglyceride (TG) plasma levels. Unexpectedly, we found that apoA-I deficiency led to redistribution of apoA-II in HDLs and an age-related increase in apoA-II levels, accompanied by larger HDL particle size and an age-related increase in TC, HDL-C and TG. Aggravated AApoAII amyloidosis was induced in Apoa1 -/-mice systemically, especially in the heart. These results indicate that apoA-I plays key roles in maintaining apoA-II distribution and HDL particle size. Furthermore, apoA-II redistribution may be the main reason for aggravated AApoAII amyloidosis in Apoa1 -/-mice. These results may shed new light on the relationship between apoA-I and apoA-II as well as provide new information concerning amyloidosis mechanism and therapy.
4 apolipoproteins, such as apoE, apoA-II (9) and apoA-IV are also shown to be active in inducing cholesterol efflux from cells and may play important roles in substituting for the loss of apoA-I (10).
ApoA-II, the second most abundant protein present in human, mouse, rat, and fish plasma HDL (11) , was long considered to be of physiologically minor importance in lipoprotein metabolism because apoA-II deficiency is not associated with a high susceptibility to coronary heart disease (12) . However, recent studies showed that apoA-II plays multiple metabolic roles in maintaining the plasma HDL pool (13) (14) (15) , promoting obesity and insulin resistance (15, 16) , augmenting monocyte responses to lipopolysaccharides (LPS) (17) , and decreasing triglyceride catabolism mainly by impairing lipoprotein lipase (LPL) activity (13) . Although human apoA-II is either atheroprotective or proatherogenic in transgenic mice depending on an atherogenic diet (18) , mouse apoA-II is proatherogenic in chow-fed transgenic mice (19) .
In human hereditary amyloidosis, a rare disorder that may cause progressive and life-threatening organ dysfunction, apoA-II can form AApoAII amyloid fibrils that are mainly deposited in the kidney (20) . In mice, apoA-II is a precursor of senile amyloid fibrils (AApoAII), which were first isolated from a senescence-accelerated inbred strain (SAMP1) having severe amyloidosis, and were later found to be present universally in mice (21) .
Mouse AApoAII amyloidosis fibrils are spontaneously deposited systemically (excluding the brain) in an age-associated manner (21) , resulting in a 20 % shortened life span for R1.P1-Apoa2 c mice (22) . In laboratory mice, there are three major alleles for Apoa2: Apoa2 a , Apoa2 b and Apoa2 c (21, 23 (14, 21, 23, 24) .
To date, the influence of apoA-I on apoA-II is not clear. Although LpA-II, which lacks apoA-I and contains apoA-II as the main apolipoprotein constituent, was found in apoA-I deficient patients (25) , there are no detailed data concerning the distribution of apoA-II. For mice lacking apoA-I, apoE is confirmed to increase in compensation, although whether this also occurs for apoA-II is not known (7, 9) . Recently, it was shown that apoA-I may also affect amyloidosis pathogenesis (26) . ApoA-I can bind amyloid β (Aβ), and decrease
Aβ-induced cytotoxicity in vitro, as well as attenuate formation of Aβ amyloid deposits on central nervous system blood vessel walls in vivo (26) . However, there are few studies concerning the role of ApoA-I in other amyloidoses, including those associated with pathological disorders such as primary (AL) amyloidosis, reactive (AA) amyloidosis, polyneuropathy (FAP), prion diseases, and familial, systemic, and sporadic amyloidosis.
Using C57BL/6J.Apoa1 -/-mice (with Apoa2 a allele), we confirmed that apoA-I deficiency results in significantly reduced plasma levels of TC, HDL-C and TG, as well as a two-fold increased apoE level that was previously described by other studies (7) . Unexpectedly, we also found that: (1) age-related increases in the levels of plasma apoA-II, TC, HDL-C and TG; (2) redistribution of apoA-II and larger HDL particle size; (3) aggravated systemic
AApoAII amyloidosis and heart amyloidosis in Apoa1 -/-mice. These results prompted us to explore how the loss of apoA-I affects the metabolism of apoA-II. Figure 1 ).
Anti-apoA-II antiserum was produced in rabbits by injecting type C apoA-II protein purified from AApoA II amyloid fibrils deposited in the liver of a SAMP1 mouse (31) . This anti-apoA-II antiserum can react specifically with plasma type A, type B and type C apoA-II on a western blot. This anti-apoA-II antiserum can also react specifically with type A, type B and type C AApoAII fibrils on a western blot or immunohistochemistry (14, 24, 32) .
Analysis of Apoa2 mRNA expression in the liver and heart.
Total RNA was extracted from livers or hearts (including the atrium cordis and ventriculus cordis) of 2 and 6-month-old mice using TRIzol Reagent (Invitrogen), followed by treatment with DNA-Free (Applied Biosystems, Foster City, CA) to remove contaminating DNA and was subjected to reverse transcription using an Omniscript RT kit (Applied and 45 sec at 72 °C for GAPDH; 24 cycles for hepatic Apoa1; 21 cycles for hepatic Apoa2;
and 32 cycles for cardiac Apoa2. Quantitative real-time RT-PCR analysis was carried out using an ABI PRISM 7500 Sequence Detection System (Applied Biosystems) with SYBR Green (Takara Bio, Tokyo, Japan), and values were normalized with respect to GAPDH.
The following primers were used: Apoa1-F 5′-GTGGCTCTGGTCTTCCTGAC -3′,
Isolation of amyloid fibrils
AApoAII(C) fibrils were isolated from the liver of a 12-month-old R1.P1-Apoa2 c mouse, a congenic strain carrying the amyloidogenic Apoa2 c allele from the SAMP1 strain in the genetic background of SAMR1 (33) , which also had severe amyloid deposition induced by intravenous injection of AApoAII(C) fibrils. AApoAII(A) fibrils were isolated from the liver of a 12-month-old C57BL/6 mouse, which had severe amyloid deposition induced by intravenous injection of AApoAII(C) amyloid fibrils. Both amyloid fibril fractions were isolated by Pras' method with some modification (14) . Isolated amyloid fibrils were suspended in distilled deionized water (DDW) at a concentration of 1.0 mg/ml and kept at -70 °C. We placed 1 ml of this mixture into a 1.5 ml Eppendorf tube and sonicated on ice for 30 s with an ultrasonic homogenizer VP-5S (Tietech Co., Ltd., Tokyo, Japan) at maximum power. This procedure was repeated 5 times at 30 s intervals. Sonicated AApoAII samples were used immediately.
Induction of amyloidosis in C57BL/6J.Apoa1 -/-mice
In this experiment, for induction of AApoAII amyloidosis, 10 or 100 μg sonicated AApoAII(C) amyloid fibrils suspended in 100 μl DDW were injected into the tail vein of 2-month-old female Apoa1 -/-and WT mice, because we have shown that AApoAII(A) amyloidosis could be induce by AApoAII(C) amyloid fibrils by cross-seeding and endogenous AApoAII(A) amyloid fibrils were deposited in C57BL/6 mice with Apoa2 a (32). After 2 or 4 months, the treated mice were sacrificed and amyloid deposition was determined. We also induced amyloidosis by the self-seeding with AApoAII(A) amyloid fibrils and compared the amyloid deposition. Control mice were injected with 100 μl DDW containing no amyloid fibrils. The mice were sacrificed by cardiac puncture under diethyl ether anesthesia, and major tissues were fixed in 10 % neutral buffered formalin, embedded in paraffin, and cut into 4 μm sections for Congo Red-staining and immunohistochemistry.
Detection of amyloid deposition
Deposition of amyloid fibrils in each mouse was identified by polarizing microscopy using
Congo Red-stained sections where green birefringence indicates the presence of amyloid.
The intensity of amyloid deposition was determined semi-quantitatively using the amyloid index (AI) as a parameter. The AI parameter represents the average degree of deposition, graded 0 to 4, in the seven organs (heart, liver, spleen, stomach, intestine, tongue and skin) examined in Congo Red stained sections. Amyloid fibril proteins were identified by immunohistochemistry using the avidin-biotin horseradish peroxidase complex method.
Specific antisera against mouse AApoAII and mouse AA were used (31). Tissues were examined by two independent observers who were blinded to the experimental protocol.
Statistical analysis
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We used the StatView software package (Abacus Concepts, Berkley, CA) for data analysis.
All data are presented as the mean ± s.d. Because the AI is nonlinear, the AI of different groups of mice was compared using the nonparametric Mann-Whitney U-test. One-way Anova and Student's t-test were used for all data except for AI.
Results

ApoA-I deficiency results in age-related increases in plasma apoA-II, cholesterol, and lipids
To determine whether apoA-I deficiency influences the metabolism of apoA-II and apoE, the major protein constituents of HDL from Apoa1 -/-mice (7,9), we determined the plasma levels of apoA-I, apoA-II and apoE of 2, 4, and 6-month-old WT and Apoa1 -/-mice by western-blot analysis after separating plasma proteins by SDS-PAGE. In WT mice, plasma levels of apoA-I (data not shown), apoA-II and apoE remained effectively constant across the ages tested. In contrast, for Apoa1 -/-mice apoA-I protein was absent and apoE levels were about two-fold higher compared to WT mice. Furthermore, the level of apoE in
Apoa1
-/-mice did not change significantly with age ( Figure 1A , C). Although the level of apoA-II decreased in 2-month-old Apoa1 -/-mice (from 23.9 ± 3.3 to 18.9 ± 2.8 mg/dl), there was a significant increase as Apoa1 -/-mice aged (21.0 ± 6.0, and 31.1 ± 5.8 mg/dl at 4, and 12 for HDL-C), while TG was one third that of normal levels (from 42.5 ± 4.0 to 13.4 ± 2.8 mg/dl). For WT mice, plasma levels of TC, HDL-C and TG did not change significantly as the mice aged. In contrast, Apoa1 -/-mice displayed significant increases in levels of plasma TC, HDL-C and TG with age. Levels of plasma TC increased to 22.8 ± 3.8 mg/dl at 4 months, and further to 34.1 ± 4.0 mg/dl at 6 months. HDL-C plasma levels increased to 17.1 ± 3.4 mg/dl at 4 months, and further to 23.4 ± 3.0 mg/dl by 6 months. Levels of plasma TG were also raised significantly from 17.4 ± 1.6 mg/dl at 4 months, to 22.0 ± 2.0 mg/dl by 6 months ( Figure 1D -F).
ApoA-I deficiency results in larger HDL particle size and redistribution of apoA-II among HDLs
To elucidate the effect of apoA-I deficiency on lipoprotein particles and the distribution of other important apolipoproteins, we determined HDL particle size by non-denaturing PAGE of plasma prestained with Sudan Black B and performed western blot analysis of plasma apolipoproteins following separation by non-denaturing PAGE. In this experiment, HDL appears monotonic ( Figure 2A ) and we marked size classes of HDL 1 , HDL 2 , and HDL 3 based on the distributions of apoA-I and apoA-II in WT mice and our previously reported results (14, 29).
There were clear differences between HDL species for WT and Apoa1 -/-mice with HDL 3 and HDL 2 being the predominant form observed in WT mice. Although there was no clear band corresponding to HDL on non-denaturing PAGE for 2-month-old Apoa1 -/-mice due to low plasma lipid levels, for 4 and 6-month-old Apoa1 -/-mice the predominant form was HDL 1 , rather than HDL 3 and HDL 2 ( Figure 2A was no clear band for apoA-IV and apoC-II from 2-month-old Apoa1 -/-mice due to low plasma concentration as was described (7, 9) , it was shown that apoA-IV distributed extensively with HDL, while apoE and apoC-II distributed mainly with HDL 1 in both WT mice and Apoa1 -/-mice. As such, apoA-I deficiency resulted in redistribution of apoA-II in an age-dependent manner, but had no obvious influence on the distribution of other apolipoproteins detected in this study ( Figure 2A ).
To confirm this result, pooled plasma from WT and Apoa1 -/-mice at 2 and/or 6 months was analyzed with a dual detection HPLC system. For WT mice, there was no marked age-dependent change in the quantity of cholesterol and HDL particle size. In contrast,
Apoa1
-/-mice showed a marked increase in the quantity of cholesterol and HDL particle size between 2 and 6 months of age ( Figure 2B ). Separation of isolated HPLC fractions by SDS-PAGE and subsequent western blot analysis of apoA-II protein clearly showed that apoA-II existed mainly in HDL particles having diameters ranging from 10.9 to 12.1 nm in 2-month-old WT mice, while 2-month-old Apoa1 -/-mice had larger HDL and LDL particles with diameters of 12.1 to 18.6 nm whose sizes further increased for 6-month-old Apoa1 -/-mice, which had HDL and LDL particles 10.9 to 28.6 nm in diameter ( Figure 2C ).
ApoA-I deficiency results in aggravated AApoAII amyloidosis
In this experiment, we used AApoAII(C) amyloid fibrils as seeds to induced AApoAII amyloidosis and further used AApoAII(A) amyloid fibrils to confirm the results. Amyloid heart (5/6) and stomach (3/6) (AI = 0.36) after 2 months and after 4 months deposits were detected in tongue (3/3), heart (3/3), stomach (3/3), intestine (3/3), liver (3/3), spleen (2/3) and skin (1/3) (AI = 1.90) ( Figure 3 , Table 1 ).
To confirm our result in Apoa1 -/-mice, 10 or 100 μg endogenous AApoAII(A) amyloid fibrils were injected. Two months after injection, mice were sacrificed and the degree of amyloid deposition determined. Again, we found that more aggravated amyloidosis was induced in Apoa1 -/-mice compared to WT mice following injection of AApoAII(A) amyloid fibrils ( Table 1 ) and we did not do the experiment of 4-month-treatment of AApoAII(A).
In summary, we confirmed that regardless of amyloid fibril type (AApoAII(C) vs.
AApoAII(A) or quantity (10 vs. 100 μg), and the amount of time following treatment (2 vs.
months), more AApoAII amyloid deposition was induced by fibril injection in Apoa1
-/-mice compared to WT mice.
ApoA-I deficiency results in higher expression of hepatic and cardiac Apoa2 mRNA.
Although Apoa2 mRNA is expressed in many organs, apoA-II is mostly synthesized by the liver (35) . To elucidate the mechanism of elevated plasma apoA-II concentration and high sensitivity to AApoA-II amyloidosis in Apoa1 -/-mice hearts, we determined the levels of hepatic and cardiac Apoa2 mRNA in 2 and 6-month-old mice by RT-PCR and real-time PCR. In WT mice, levels of hepatic and cardiac Apoa2 mRNA did not change with age until 6 months, whereupon there was about 5,000 times lower levels of cardiac Apoa2 mRNA than that of the liver (data not shown). Interestingly, Apoa1 -/-mice had higher expression of hepatic Apoa2 mRNA (1.2 times at 2 months and further 1.5 times at 6 months) and cardiac Apoa2 mRNA (about 5 times at 2 and 6 months). In WT mice, there was no significant change in HDL-C and apoA-II concentrations 2 or 4 months after injection of 10 or 100 μg AApoAII(C) amyloid fibrils. In Apoa1 -/-mice, there was no significant change in HDL and apoA-II plasma concentrations 2 months after fibril injection. After four months, however, there was a significant decrease in the plasma concentrations of HDL and apoA-II when 100 μg AApoAII(C) amyloid fibrils was injected, as compared to control mice ( Figure 5A , B, D).
To determine whether AApoAII amyloidosis influences lipoprotein particles, we determined HDL particle size by non-denaturing PAGE. We observed no clear change in HDL sizes for either Apoa1 -/-or WT mice ( Figure 5C ), which was supported by HPLC analysis (data not shown).
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Discussion
In this study, we focused on how apoA-I deficiency influences apoA-II and AApoAII amyloidosis in mice. We confirmed that apoA-I deficiency resulted in a significant reduction of TC, HDL-C and TG but increased plasma apoE levels (7, 9) .Unexpectedly, we found that apoA-I deficiency results in: (1) age-related increases in apoA-II, TC, HDL-C and TG plasma levels; (2) redistribution of apoA-II and larger sized HDL particles; (3) aggravated AApoAII amyloidosis and heart amyloidosis.
ApoA-I plays key roles in lipid transport and metabolism mainly by activating LCAT and maintaining RCT (3, 4) . As such, it is not surprising that human apoA-I overexpression results in elevated HDL-C levels in mice (14) and that apoA-I-deficiency causes a marked reduction in HDL-C levels in humans and mice (5, 6, 7).
ApoA-II is also known to be important for RCT and maintaining the plasma HDL pool.
Human apoA-II exerts at least part of its pro-atherogenic effect by counteracting the antioxidant properties of HDL rather than by impairing macrophage-specific RCT (36, 37).
Furthermore, in hApoa2 transgenic mice, RCT from macrophages to liver and feces was enhanced under chow-fed diet (38) . On the other hand, mice that overexpress mApoa2 have increased HDL-C (14) and apoA-II deficient mice have dramatically decreased HDL-C (15).
In this study, we found that apoA-II levels in apoA-I deficient mice at 2 and 4 months of age did not differ significantly from WT mice, but by 6 months of age, apoA-II levels markedly increased to about 1.5-fold more than in 6-month-old WT mice. Although Apoa2 mRNA is expressed in many organs, apoA-II is mostly synthesized by the liver (35) . We found that there was a higher expression of hepatic Apoa2 mRNA in apoA-I deficient mice (1.2 and 1.5 times at 2 and 6 months, respectively). These changes may account for the age-dependent increase in apoA-II levels in apoA-I deficient mice. In addition, there are other possibilities that could account for these changes, such as alterations in the secretion and metabolism of apoA-II in apoA-I deficient mice. We believe that the increased apoA-II levels may play more important roles than simply substituting for the loss of apoA-I. The role of apoA-II during RCT and its powerful ability to impair LPL activity (13) may explain the observed age-related increases in plasma cholesterol and TG.
In humans and mice, most apoA-II exists as an integral protein constituent of LPA-I/A-II, which is present in HDL 3 . Interestingly, a minor HDL species characterized by having apoA-II as its major protein constituent (LP A-II) was isolated from normolipidemic subjects and apoA-I deficient patients (25) . LP-A-II also can interact with other apolipoproteins to form LPA-II:B or LPA-II:B:C:D:E complexes in VLDL of apoA-I deficient patients (25, 39) . The lipid profile of LPA-II from apoA-I deficient patients is characterized by a significantly higher percentage of triglycerides and a lower percentage of phospholipids compared to LPA-II from normolipidemic subjects (25) . These differences suggest that human lipoprotein particles containing apoA-II from apoA-I-deficient patients have larger sizes than normal LPA-I/A-II particles. In this study, we clearly showed that apoA-II in Apoa1 -/-mice mainly exists in HDL 3 at 2 months as expected, whereas the predominant species at 4 and 6 months is HDL 1 . At the same time, the size of HDL from In mice, AApoAII amyloid deposits first form in the tongue, stomach and intestine, then extend to other tissues, with the heart moderately susceptible to AApoAII amyloidosis (14) .
In this study, we showed that hearts of Apoa1 -/-mice were highly susceptible to AApoAII amyloidosis. Why this result occurred is unclear, but one possible explanation is that apoA-I deficiency may alter the microenvironment of the heart. The heart has significant muscle content, but we noticed that there was no obvious AApoAII amyloid deposition in the muscle tissues from the tongues, intestines and stomachs of Apoa1 -/-mice (data not shown). As such, heart may have tissue specificity to AApoAII amyloidosis in Apoa1 -/-mice. Although there is very low expression of Apoa2 mRNA in the heart, we found that there was about 5-fold higher expression of cardiac Apoa2 mRNA in Apoa1 -/-mice. This higher endogenous apoA-II may at least in part account for the heart's higher susceptibility to AApoAII amyloidosis.
In humans, the heart is also highly vulnerable to some types of amyloidoses, such as AL and AA amyloidosis, FAP, and isolated atrial amyloidosis (42) . There is no effective treatment for amyloid heart disease, which leads to an infiltrative/restrictive cardiomyopathy (42 research on apoA-I may help define the mechanism of amyloid heart disease, which may aid the development of therapeutic strategies.
We also detected a significant decrease in HDL and apoA-II plasma concentrations 4 months after severe amyloidosis was induced in Apoa1 -/-mice by injection of 100 μg AApoAII(C) amyloid fibrils. In earlier studies, we confirmed that the serum level of apoA-II decreased during amyloidosis in SAMP1 mice (43) . Since aggravated AApoAII amyloidosis did not alter the synthesis of apoA-II but rather accelerated apoA-II catabolism (43) , the decrease in HDL and apoA-II plasma concentrations may be the result of, rather than the reason for, severe amyloidosis.
In conclusion, these results indicate that apoA-I plays key roles in maintaining apoA-II distribution and HDL particle size. Furthermore, the redistribution of apoA-II may be the main reason for aggravated AApoAII amyloidosis in Apoa1 -/-mice. ApoA-II may thus play important roles in substituting for the loss of apoA-I. These findings should provide novel insights for the relationship between apoA-I and apoA-II and the mechanism of amyloidosis. and F). G, H, The grade of amyloid deposition in the heart and system was determined using Congo Red-stained sections 2 and 4 months after mice were injected with 10 or 100 μg AApoAII(C) amyloid fibrils. Systemic amyloid score represents the average degree of deposition, graded 0 to 4, in the seven organs examined (heart, liver, spleen, stomach, intestine, tongue and skin). Numbers above the columns represent amyloid positive mice/examined mice. BV, blood vessels; End, endocardium; Ep, epicardium; N, nucleus. 
